Page last updated: 2024-12-07
kryptogenin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
kryptogenin: from carp bile [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 21117640 |
| CHEMBL ID | 389341 |
| CHEBI ID | 81367 |
| MeSH ID | M0051927 |
Synonyms (26)
| Synonym |
|---|
| nsc 93751 |
| 3-beta,26-dihydroxycholest-5-ene-12,22-dione [french] |
| (3-beta,25r)-3,26-dihydroxycholest-5-ene-16,22-dione |
| 3beta,26-dihydroxycholest-5-ene-16,22-dione |
| cholest-5-ene-16,22-dione, 3beta,26-dihydroxy-, (20s,25r)- |
| cholest-5-ene-16,22-dione, 3,26-dihydroxy-, (3-beta,25r)- |
| cryptogenine [french] |
| cholest-5-ene-16,22-dione, 3-beta,26-dihydroxy-, (20s,25r)- |
| cryptogenin |
| kryptogenin |
| CHEMBL389341 |
| chebi:81367 , |
| C17891 |
| LMST01010341 |
| 16,22-dioxo-25s-methyl-cholest-5-en-3beta-ol |
| cryptogenine |
| 3-beta,26-dihydroxycholest-5-ene-12,22-dione |
| bxc9x8b37j , |
| unii-bxc9x8b37j |
| GDKGOXUWEBGZBY-WQTURIIHSA-N |
| 3,26-dihydroxycholest-5-ene-16,22-dione # |
| cholest-5-ene-16,22-dione, 3,26-dihydroxy-, (3.beta.,25r)- |
| cholest-5-ene-16,22-dione, 3.beta.,26-dihydroxy-, (20s,25r)- |
| (3.beta.,25r)-3,26-dihydroxycholest-5-ene-16,22-dione |
| Q27155304 |
| AKOS040752280 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| cholanoid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID292677 | Antitumor activity against HeLa cells at 0.1 uM by MTT assay | 2007 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1 | Synthesis of bisdesmosidic kryptogenyl saponins using the 'random glycosylation' strategy and evaluation of their antitumor activity. |
| AID292678 | Antitumor activity against HeLa cells at 10 nM by MTT assay | 2007 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1 | Synthesis of bisdesmosidic kryptogenyl saponins using the 'random glycosylation' strategy and evaluation of their antitumor activity. |
| AID292676 | Antitumor activity against HeLa cells at 1 uM by MTT assay | 2007 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1 | Synthesis of bisdesmosidic kryptogenyl saponins using the 'random glycosylation' strategy and evaluation of their antitumor activity. |
| AID292679 | Antitumor activity against HeLa cells by MTT assay | 2007 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1 | Synthesis of bisdesmosidic kryptogenyl saponins using the 'random glycosylation' strategy and evaluation of their antitumor activity. |
| AID292675 | Antitumor activity against HeLa cells at 10 uM by MTT assay | 2007 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1 | Synthesis of bisdesmosidic kryptogenyl saponins using the 'random glycosylation' strategy and evaluation of their antitumor activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||